RxDoctor Payments Data

Hanna Song, NP

Nurse Practitioner · Duarte, CANPI 1174134472

Payments from drug & device makers

$8,582in general payments, 2019–2025

Across 326 payments — averaging $26.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Lilly USA, LLC$488
  • Pfizer$441
  • Incyte Corporation$394
  • AstraZeneca$339
  • Karyopharm Therapeutics Inc.$323
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$7,05182%
  • Education$5166%
  • Other$1,01512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,582 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$20,722
Medicare patients
60
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate52$843,172
PromactaEltrombopag Olamine16$330,201
BosulifBosutinib13$183,006
PrevymisLetermovir17$129,828
CresembaIsavuconazonium Sulfate17$115,546
SprycelDasatinib16$63,748
Deferasirox22$31,581
Posaconazole22$28,152
EliquisApixaban11$11,172
Atovaquone13$7,610
Tacrolimus13$3,236
Acyclovir74$1,020
Ursodiol11$945
FenofibrateFenofibrate Nanocrystallized21$383
Pantoprazole Sodium31$333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$394$843,17252 claims
NovartisPromacta$1,878$330,20116 claims
PfizerBosulif, Eliquis$441$194,17724 claims
MerckPrevymis$231$129,82817 claims
Astellas Pharma US IncCresemba$298$115,54617 claims
E.r. Squibb & Sons, L.L.C.Sprycel$98$63,74816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Duarte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →